BELLEVUE, Wash., Aug. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today reported financial results for the three and six months ended June 30, 2008. The Company will host a live conference call today, August 7, 2008, at 11:30 a.m. (Eastern Daylight Time).
Daniel O. Wilds, SCOLR Pharma's President and CEO, said, "We are pleased with the significant progress made during the second quarter maintaining a sharp focus on advancing our two lead product candidates, supporting our corporate partnerships and collaborations, aggressively managing our expenses, and assuring that we have sufficient operating capital through the end of 2009.
As reported during the period, we received the FDA's response to our special protocol assessment that provided further Phase III study design clarity for our over-the-counter (OTC) 12-hour extended-release (ER) ibuprofen product candidate. Subsequently, we incorporated the FDA's suggestions in our study protocol and initiated this important pivotal trial on June 30, 2008. In addition, we announced the submission of an Abbreviated New Drug Application (ANDA) for our OTC 12-hour ER pseudoephedrine product candidate in early August. We also announced the buy-out of our corporate facility lease under which we will receive an aggregate of $4.1 million. By continuing to focus spending on our lead product candidates, limiting additional drug development initiatives to those already partnered and in active collaborations, we expect that the net proceeds from the lease buy-out and current financial resources together with continuing expense management will be sufficient to fund our operations through 2009. "
Total revenues, which consist of royalty revenue from our collaboration agreements, decreased 34%, or $142,485 to $279,571 for the three months ended June 30, 2008, compared to $422,056 for the same period in 2007. This decrease is primarily due to lower royalty income from our relationship with Perrigo. However, royalty income increased 5%, or $14,016 to $279,571 in the three months ended June 30, 2008, compared to $265,555 for the first quarter of 2008 as Perrigo increased sales to a major national retailer.
Total revenues of $545,126 decreased 65% or $996,849 for the six months ended June 30, 2008, compared to $1.5 million for the same period in 2007. The higher total revenues for 2007 were primarily due to approximately $795,000 of research and development fees and licensing revenues from an agreement terminated in the first quarter of 2007.
Net loss increased less than 1%, or $1,380 to $2.1 million for the three months ended June 30, 2008, compared to $2.1 million for the same period in 2007. Net loss for the six months ended June 30, 2008, increased 2%, or $98,429 to $4.1 million compared with a net loss of $4.0 million for the same period in 2007. The increased losses were primarily due to lower revenues and other income, offset by lower operating costs.
Total operating expenses for the second quarter of 2008 decreased 7% to $2.5 million compared to $2.7 million for the same period in 2007. Operating expenses decreased 19% to $4.8 million for the six months ended June 30, 2008 from $5.9 million for the same period in 2007. The decreases in operating expenses were primarily due to reductions in advertising and tradeshow expense, research and development, and outside services.
In May 2008, we entered into an agreement to terminate the existing lease of our corporate facility for consideration of $4.1 million. Under the terms of the agreement, $1.0 million was paid upon execution of the agreement and the remaining $3.1 million is due when we vacate the premises, at which time the amount will be recognized as a gain.
We had approximately $8.0 million in cash and cash equivalents, and $564,000 in restricted cash as of June 30, 2008. In addition, we expect to receive an additional $3.1 million in October 2008, related to our Lease Termination Agreement. We believe that our cash, cash equivalents and short- term investments will be sufficient to fund our operations at planned levels through the end of 2009.
As previously announced, SCOLR Pharma will host a conference call on August 7, 2008, at 11:30 a.m. (Eastern Daylight Time). Shareholders and other interested parties may participate in the conference call by dialing +1 888 680 0878 (domestic) or +1 617 213 4855 (international) and entering access code 26733631, a few minutes before 11:30 a.m. ET on August 7, 2008. The call will also be broadcast live on the Internet at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.
A replay of the conference call will be accessible two hours after its completion through August 21, 2008, by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering access code 55141034. The call will also be archived for 90 days at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.
About SCOLR Pharma:
Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.373.0171 or visit http://www.scolr.com/.
This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements concerning
the adequacy of our capital resources to fund our operations. These
forward-looking statements involve risks and uncertainties, including
activities, events or developments that we expect, believe or anticipate
will or may occur in the future. A number of factors could cause actual
results to differ from those indicated in the forward-looking statements,
including our ability to successfully develop new formulations and complete
research and development, including pre-clinical and clinical studies, our
ability to raise additional funds, the continuation of arrangements with
our product development partners and customers, competition, government
regulation and approvals, and general economic conditions. For example, if
our clinical trials are not successful or take longer to complete than we
expect, we may not be able to develop and commercialize our products. And
we may not obtain regulatory approval for our products, which would
materially impair our ability to generate revenue. Additional assumptions,
risks and uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and Exchange
Commission. Such filings are available on our website or at http://www.sec.gov.
You are cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ materially
from those set forth in the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements to
reflect subsequent events or circumstance.
SCOLR Pharma, Inc.
June 30, December 31,
Cash and cash equivalents $8,024,052 $11,825,371
Accounts receivable 276,848 225,900
Interest and other receivables 1,295 16
Prepaid expenses and other assets 576,176 432,213
Total current assets 8,878,371 12,474,500
Property and Equipment - net of accumulated
depreciation of $1,132,711 and
$964,738, respectively 580,958 748,931
Intangible assets - net of accumulated
amortization of $422,087 and
$385,452, respectively 515,663 464,023
Restricted cash 564,000 -
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable $230,320 $757,420
Accrued expenses 454,956 586,849
Deferred gain - lease termination 1,000,000 -
Current portion of term loan 83,858 80,047
Total current liabilities 1,769,134 1,424,316
Long-term portion of term loan 68,216 111,119
Total liabilities 1,837,350 1,535,435
Commitments and Contingencies
Preferred stock, authorized 5,000,000 shares,
$.01 par value, none issued or outstanding - -
Common stock, authorized 100,000,000 shares,
$.001 par value, 41,130,270 and 40,991,385
issued and outstanding as of June 30, 2008,
and December 31, 2007, respectively 41,130 40,991
Additional paid-in capital 70,601,489 69,945,666
Accumulated deficit (61,940,977) (57,834,638)
Total stockholders' equity 8,701,642 12,152,019
SCOLR Pharma, Inc.
CONDENSED STATEMENTS OF OPERATIONS
Three months ended Six months ended
June 30, June 30,
2008 2007 2008 2007
Licensing fees $- $- $- $173,077
Royalty income 279,571 422,056 545,126 747,676
development income - - - 621,222
Total revenues 279,571 422,056 545,126 1,541,975
Marketing and selling 191,047 225,374 428,739 475,256
development 1,197,321 1,377,499 2,080,533 3,173,374
administrative 1,062,646 1,112,244 2,294,930 2,288,742
expenses 2,451,014 2,715,117 4,804,201 5,937,372
Loss from operations (2,171,443) (2,293,061) (4,259,076) (4,395,397)
Other income (expense)
Interest income 59,353 185,345 159,671 390,321
Interest expense (3,859) (5,615) (8,172) (5,775)
Other 1,238 - 1,238 2,941
Total other income
(expense) 56,732 179,730 152,737 387,487
Net loss $(2,114,711) $(2,113,331) $(4,106,339) $(4,007,910)
Net loss per
and diluted $(0.05) $(0.06) $(0.10) $(0.11)
Shares used in
net loss per
share 41,042,090 38,130,640 41,033,770 38,107,698
|SOURCE SCOLR Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved